Original articles

Clinical analysis of 88 patients with myeloproliferative neoplasm

Expand
  • Department of Hematology, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China

Received date: 2019-02-27

  Online published: 2020-04-25

Abstract

Objective: To explore the clinical features of 88 patients with myeloproliferative neoplasm(MPN) for analyzing the differences between prefibrotic primary myelofibrosis (pre-PMF), essential thrombocytopenia(ET), overt primary myelofibrosis (overt-PMF), and emphasizing the clinical importance of the diagnosis of pre-PMF. Methods: Eighty- eight patients with MPN at our hospital from January 2015 to January 2018 were enrolled. The clinical data including disease classification, routine blood test, splenomegaly, megakaryocyte count, degree of fibrosis in bone marrow and related gene mutations were collected and analyzed. Results: Of the 88 patients, the median age at diagnosis was 61 years (range 20-88 years), 32(36%) patients were over 65 years old, 46 (52%) were male, and 22 (25%) had splenomegaly. There were 51 cases (58%) with JAK2 V617F mutation, 5 cases (6%) with CALR mutation, 2 cases (2%) with MPL mutation, and 30 cases (34%) with triple negative. There were 20 cases of polycythemia vera (PV), 23 cases of ET, and 45 cases of primary myelofibrosis (PMF), including 23 cases of pre-PMF (51% of PMF) and 22 cases of overt-PMF (49% of PMF). Among all the patients with overt-PMF, the mutation rate of CALR gene was as high as 18% (4/22). Clinical manifestations of pre-PMF is milder than that of overt-PMF, with a lower ratio of low hemoglobin and lower platelet count, and a lower mean lactic acid dehydrogenase (P values of 0.048, 0.034, 0.037, respectively). The clinical manifestations of patients with pre-PMF were similar to those of patients with ET, however, the former had a higher proportion of splenomegaly and leukocytosis than the latter (P=0.043 and 0.007). Follow-up showed that patients with ET had longer survival than patients with pre-PMF (P=0.038). In patients with pre-PMF, triple-negative patients had a lower median age and greater number of splenomegaly than patients with JAK2 mutation (P=0.030 and 0.017). Conclusion: MPN is a group of hematological diseases with heterogeneous clonality. Different clinical manifestations and prognosis are presented in patients with pre-PMF and patients with overt-PMF, and it is necessary to distinguish the two diseases. The clinical manifestations of pre-PMF and ET are similar, but the prognosis is different. It is extremely important to distinguish the two diseases by histomorphological diagnosis combined with secondary clinical criteria.

Cite this article

XIAO Chao, TAO Ying, SONG Luxi, ZHAO Youshan, WU Lingyun, CHANG Chunkang . Clinical analysis of 88 patients with myeloproliferative neoplasm[J]. Journal of Diagnostics Concepts & Practice, 2020 , 19(02) : 115 -121 . DOI: 10.16150/j.1671-2870.2020.02.004

References

[1] Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms[J]. Leukemia, 2008, 22(1):14-22.
[2] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[3] Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood,2009, 114(5):937-951.
[4] Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis[J]. Blood, 2014, 124(16):2507-2513.
[5] Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2017, 92(1):94-108.
[6] Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experie-nce[J]. Mayo Clin Proc, 2012, 87(1):25-33.
[7] Takenaka K, Shimoda K, Uchida N, et al. Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan[J]. Int J Hematol, 2017, 105(1):59-69.
[8] Gisslinger H. Pre-PMF emerging as important subgroup of MPN[J]. Blood, 2017, 129(24):3142-3144.
[9] Barosi G. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter[J]. Best Pract Res Clin Haematol, 2014, 27(2):129-140.
[10] Michiels JJ, Kutti J, Stark P, et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis[J]. Neth J Med, 1999, 54(2):46-62.
[11] Jeryczynski G, Thiele J, Gisslinger B, et al. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease[J]. Am J Hematol, 2017, 92(9):885-891.
[12] Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis[J]. N Engl J Med, 2010, 363(12):1117-1127.
[13] Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies[J]. Haematologica, 2014, 99(2):292-298.
[14] Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)[J]. Blood, 2010, 115(9):1703-1708.
[15] Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J]. N Engl J Med, 2012, 366(9):799-807.
[16] Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling[J]. Immunol Rev, 2009, 228(1):273-287.
[17] Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons[J]. Leukemia, 2014, 28(7):1472-1477.
[18] Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disor-ders[J]. Nat Rev Cancer, 2007, 7(9):673-683.
[19] Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis[J]. N Engl J Med, 2012, 366(9):787-798.
Outlines

/